bosentan anhydrous has been researched along with Centriacinar Emphysema in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P; Chen, Y; Droma, Y; Hanaoka, M; Kubo, K; Voelkel, NF | 1 |
| Chen, P; Chen, Y; Keishi, K; Masayuki, H; Peng, H; Yunden, D | 1 |
| Imanishi, J; Miwa, Y; Shimizu, M; Takano, T | 1 |
3 other study(ies) available for bosentan anhydrous and Centriacinar Emphysema
| Article | Year |
|---|---|
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats.
Topics: Animals; Antihypertensive Agents; Blotting, Western; Bosentan; Caspase 3; Endothelin A Receptor Antagonists; Endothelin-1; Immunohistochemistry; In Situ Nick-End Labeling; Injections, Intraperitoneal; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Oxidative Stress; Peptides, Cyclic; Pulmonary Emphysema; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Smoking; Sulfonamides | 2010 |
[The mechanism and pulmonary-protective effects of endothelin-1 receptor antagonist in chronic obstructive pulmonary diseases rat model].
Topics: Animals; Antihypertensive Agents; Apoptosis; Bosentan; Caspase 3; Endothelin A Receptor Antagonists; Interleukin-1beta; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Peptides, Cyclic; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Rats; Rats, Sprague-Dawley; Sulfonamides; Tumor Necrosis Factor-alpha | 2010 |
Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Pulmonary Emphysema; Sulfonamides; Vasodilator Agents | 2011 |